Previous 10 | Next 10 |
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 PR Newswire CRANFORD, N.J. , Jan. 11, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical com...
Citius Pharmaceuticals press release ( NASDAQ: CTXR ): FY GAAP EPS of -$0.23 beats by $0.01 . As of September 30, 2022, the Company had $41.7 million in cash and cash equivalents. The Company estimates that its available cash resources will be sufficient to fund its operat...
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update PR Newswire $41.7 million in cash and cash equivalents as of September 30, 2022 ; extends runway through December 2023 Mino-Lok® Phase 3 trial closer to...
Summary Assertio Holdings is a pharmaceutical company based on a niche model that is focused on digital, non-personal promotion. Last Q3 showed great revenue and cash flow growth. The company's growth strategy is based on market acquisitions. The share price valuation seems to b...
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma PR Newswire Prescription Drug User Fee Act (PDUFA) t...
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program PR Newswire Net operating losses converted into non-dilutive capital for ongoing R&D programs CRANFORD, N.J. , Nov. 21, 2022 /PRNewswire/ -- Citius Pharm...
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire Oral and Poster Presentations to Highl...
Summary Citius Pharmaceuticals, Inc. has a handful of catalysts set to occur in the next few months. Of these, some are critical to extending its cash runway far enough to reach commercialization of its major products, and are therefore a "must complete" by the company. Invest...
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 PR Newswire CRANFORD, N.J. , Oct. 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 PR Newswire CRANFORD, N.J. , Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-sta...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...